MDTHealthcare · Medical DevicesThe 30 Wall Street analysts covering Medtronic Plc hold a median 12-month price target of $106 — +0.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Medtronic Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (57): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MDT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.9% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | BTIG | Maintains | Buy | $100 → $99 |
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $95 |
| 30 Sept 2026 | TD Cowen | Reiterates | Buy | $110 |
| 30 Sept 2026 | TD Cowen | Reiterates | Buy | — |
| 3 Sept 2026 | UBS | Maintains | Buy | — |
| 3 Sept 2026 | UBS | Maintains | Buy | $100 → $110 |
| 2 Sept 2026 | B of A Securities | Maintains | Buy | $95 → $110 |
| 2 Sept 2026 | B of A Securities | Maintains | Buy | — |
| 2 Sept 2026 | Baird | Maintains | Neutral | $91 → $100 |
| 2 Sept 2026 | Baird | Maintains | Neutral | — |
| 2 Sept 2026 | RBC Capital | Reiterates | Outperform | $118 |
| 2 Sept 2026 | RBC Capital | Reiterates | Outperform | — |
| 2 Sept 2026 | Stifel | Maintains | Hold | $80 → $95 |
| 2 Sept 2026 | Stifel | Maintains | Hold | — |
| 2 Sept 2026 | Truist Securities | Reiterates | Hold | $86 → $99 |
| 2 Sept 2026 | Truist Securities | Reiterates | Hold | — |
| 2 Sept 2026 | Wells Fargo | Maintains | Overweight | $102 → $104 |
| 2 Sept 2026 | Wells Fargo | Maintains | Overweight | — |
| 1 Sept 2026 | BTIG | Maintains | Buy | $91 → $100 |
| 1 Sept 2026 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MDT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Medtronic Plc returned +20.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 33% of US stocks
Cheaper than 33% of US stocks
Cheaper than 25% of US stocks
Higher than 61% of US stocks
Higher than 72% of US stocks
Higher than 78% of US stocks
Higher than 78% of US stocks
Higher than 76% of US stocks
Higher than 65% of US stocks
Higher than 77% of US stocks
Higher than 85% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medtronic Plc has a market value of $134.3B and an enterprise value of $146.4B.
Revenue in the twelve months to 31 July 2026: $37.5B. The latest quarter grew 13.7% year on year.
Net income over the same four quarters: $5.3B, a 14.0% net margin.
Diluted earnings per share, trailing twelve months: $4.06.
Free cash flow in the twelve months to 31 July 2026: $6.1B.
Medtronic Plc spent $1.2B on share buybacks and $3.6B on dividends in the twelve months to 31 July 2026.
Trailing P/E: 25.9×; forward P/E: 16.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.74%, paying out 70% of earnings.
Medtronic Plc employs 95,000 people — $395K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medtronic Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Medtronic said it will report results for its second quarter of fiscal 2027 on November 24, 2026. The quarter ended October 30, 2026, and a summary financial information release is scheduled for 5:45 a.m.
Why it matters — MDT watchers will receive the company’s financial update for the quarter on that date.
MarketWatch’s headline says 12 stocks are considered good bets to outperform the 10-year Treasury over the next decade; the excerpt describes them as investment newsletters’ favorite Dividend Aristocrat stocks. The provided text does not identify the stocks.
Why it matters — A Medtronic watcher may note the item’s focus on Dividend Aristocrats, but the excerpt does not establish whether MDT is among the stocks discussed.
Medtronic reported that the SPYRAL AFFIRM post-approval study found statistically significant and clinically meaningful blood pressure reductions six months after treatment with its Symplicity Spyral renal denervation system, across office, home, and 24-hour ambulatory measures, with no increase in antihypertensive medications. Nearly nine in 10 patients experienced a clinical benefit, and Medtronic received FDA approval for a U.S. labeling update.
Why it matters — The results and labeling update add clinical evidence for a Medtronic blood pressure treatment and may be relevant to watchers tracking the product’s clinical and regulatory progress.
Medtronic closed at $99.36, up 2.92% from its previous close, while the broader market fell, according to the excerpt.
Why it matters — MDT watchers may note the stock’s daily gain relative to the market’s decline.
The Motley Fool headline discusses dividend stocks to buy with $5,000 in November. The excerpt says AbbVie’s profits are soaring after it weathered the loss of Humira, while J&J’s streamlining efforts are paying off.
Why it matters — The excerpt focuses on AbbVie and J&J, not Medtronic, so it offers no specific information about MDT.
The 30 Wall Street analysts covering Medtronic Plc have a median 12-month price target of $106, with estimates ranging from $85 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 30 analysts covering Medtronic Plc, 20 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medtronic Plc 89 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Medtronic Plc ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 30 analysts implies +0.9% from the last close, and Ticker Nerd's factor model ranks Medtronic Plc 89 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medtronic Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $121 over the next 12 months.
Medtronic Plc returned +20.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring of a wide range of chronic and complex conditions.
The most recent item we track (PRNewsWire, 4 Nov 2026): "Medtronic to announce financial results for its second quarter of fiscal year 2027". Medtronic said it will report results for its second quarter of fiscal 2027 on November 24, 2026. The quarter ended October 30, 2026, and a summary financial information release is scheduled for 5:45 a.m.
Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring of a wide range of chronic and complex conditions. Medtronic supplies hospitals, clinics, physicians, and other healthcare providers with products such as cardiac rhythm devices, neuromodulation systems, surgical instruments, insulin pumps, and patient monitoring technologies. The company serves healthcare systems across the United States and international markets, making it an important participant in modern medical device supply chains and clinical care delivery. Headquartered in Dublin, Ireland, Medtronic plc focuses on technologies used in everyday care and advanced procedures, helping healthcare professionals address conditions across many specialties.
CEO Mr. Geoffrey Straub Martha · 95,000 employees · Ireland · https://www.medtronic.com
